Parathyroid Hormone Replacement Therapy in Hypoparathyroidism: A Meta-Analysis

Area of Science:

• Endocrinology
• Metabolic Bone Disease

Background:

• Hypoparathyroidism is a rare endocrine disorder characterized by insufficient parathyroid hormone (PTH) production.
• Current management often involves calcium and active vitamin D supplementation, which can lead to complications.
• The potential role of PTH replacement therapy in managing hypoparathyroidism requires further investigation.

Purpose of the Study:

• To conduct a meta-analysis of randomized controlled trials (RCTs) evaluating the efficacy of human parathyroid hormone (PTH) replacement therapy in patients with hypoparathyroidism.
• To assess the impact of PTH (1-34) and PTH (1-84) on key biochemical markers, including serum calcium, phosphate, and vitamin D metabolites.

Main Methods:

• A systematic search of Medline, Cochrane, EMBASE, and Google Scholar databases was performed up to January 13, 2015.
• Five RCTs (n=245) comparing PTH (1-34) or PTH (1-84) with placebo or calcitriol were included in the meta-analysis.
• Outcomes assessed included serum calcium, phosphate, 1,25-dihydroxyvitamin D, 25-dihydroxyvitamin D, and 24-hour urine calcium excretion.

Main Results:

• Neither PTH (1-34) nor PTH (1-84) significantly altered serum calcium levels compared to controls.
• PTH (1-34) therapy led to a significant reduction in 24-hour urine calcium excretion (p≤0.012).
• PTH (1-84) significantly decreased serum phosphate levels (p=0.000), while PTH (1-34) showed a non-significant trend towards decreasing phosphate (p=0.053).
• Both PTH therapies were associated with a significant decrease in serum 25-dihydroxyvitamin D levels (p≤0.04) but did not affect serum 1,25-dihydroxyvitamin D levels (p≥0.606).

Conclusions:

• Despite limited RCT data, PTH (1-34) replacement therapy may help normalize serum calcium by reducing urinary calcium excretion in hypoparathyroidism.
• Both PTH (1-34) and PTH (1-84) replacement therapies may play a role in maintaining 1,25-dihydroxyvitamin D levels through their effect on 25-dihydroxyvitamin D.
• Further research with larger trials is warranted to fully elucidate the long-term benefits and optimal use of PTH replacement therapy in hypoparathyroidism.